PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

Journal of Clinical Investigation

Volumn 110, Issue 7, 2002, Pages 923-932

  Panigrahy, Dipak ^a   Singer, Samuel ^b,c   Shen, Lucy Q ^a   Butterfield, Catherine E ^a   Freedman, Deborah A ^a   Chen, Emy J ^a   Moses, Marsha A ^a   Kilroy, Susan ^a   Duensing, Stefan ^d   Fletcher, Christopher ^b   Fletcher, Jonathan A ^b   Hlatky, Lynn ^d   Hahnfeldt, Philip ^d   Folkman, Judah ^a   Kaipainen, Arja ^a,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE; TROGLITAZONE; VASCULOTROPIN; 2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELL RECEPTOR; FIBROBLAST GROWTH FACTOR 2; LIGAND; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CAPILLARY ENDOTHELIUM; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; CANCER INVASION; CATTLE; METASTASIS; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIGANDS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0036771776     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215634     Document Type: Article

References (48)

1. Rosen, E.D., and Spiegelman, B.M. 2001. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276:37731-37734.
2. Barak, Y., et al. 1999. PPAR-γ is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
3. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994. Stimulation ofadipogenesis in fibroblasts by PPARγ 2, a lipid activated transcription factor. Cell. 79:1147-1156.
4. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. 1998. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
5. Mueller, E., et al. 1998. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell. 1:465-470.
6. Sarraf, P., et al. 1998. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4:1046-1052.
7. Tontonoz, P., et al. 1991. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA. 94:237-241.
8. Elstner, E., et al. 1998. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid and receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA. 95:8806-8811.
9. Kubota, T., et al. 1998 Ligand for peroxisome-activated receptor γ (Troglitazone) has potent antitumor effect against human prostate cancer both in vivo and in vitro. Cancer Res. 58:3344-3352.
10. Nakashiro, K., et al. 2001. Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells. Am. J. Pathol. 159:591-597.
11. Ohta, K., Endo, T., Haraguchi, K., Hershman, J.M., and Onaya, T. 2001. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoprosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol Metab. 86:2170-2177.
12. Palakurthi, S.S., Aktas, H., Grubissich, L.M., Mortensen, R.M., and Halperin, J.A. 2001. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 61:6213-6218.
13. Folkman, J. 2000. Tumor angiogenesis. In Cancer medicine. 5th edition. J.F. Holland et al., editors. B.C. Decker Inc. Hamilton, Ontario, Canada. 132-152.
14. Marx, N., Bourcier, T., Sukhova, G.K., Libby, P., and Plutzky, J. 1999. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb. Vasc. Biol. 19:546-551.
15. Xin, X., Yang, S., Kowalskij, and Gerritsen, M.E. 1999. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274:9116-9121.
16. 2. J. Biol. Chem. 274:17042-17048.
17. Gralinski, M.R., Rowse, P.E., and Breider, M.A. 1998. Effects of troglirazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro. J. Cardiovasc. Pharmacol. 31:909-913.
18. Murata, T., et al. 2000. Peroxisome proliferator-activated receptor-γ ligands inhibit choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41:2309-2317.
19. Inoue, K., et al. 2001. Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res. 21:2471-2476.
20. Slaron, J.W., Perrotte, P., Inoue, K., Dinney, C., and Fidler, I.J. 1999. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5:2726-2734.
21. D'Amato, R., Loughnan, M.S., Flynn, E., and Folkman, J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:4082-4085.
22. Masferrer, J.L., et al. 2000 Antiangiogenic and antitumor activities of cyclooxgenase-2 inhibitors. Cancer Res. 60:1306-1311.
23. O'Reilly, M.S., et al 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma. Cell. 79:315-328.
24. Stephenson, R.A., et al. 1992. Metastatic model for human prostate cancer using orthoropic implantation in nude mice. J. Natl. Cancer Inst. 84:951-957.
25. Braunhut, S., and Moses, M. 1994. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J. Biol. Chem. 269:13472-13479.
26. Moses, M.A., Sudhalter, J., and Langer, R. 1990. Identification of an inhibitor of neovascularization from cartilage. Science. 248:1408-1410.
27. Hauser, S., et al. 2000. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand dependent activation. J. Biol. Chem. 275:18527-18533.
28. Moses, M.A., et al. 1999. Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl. Acad. Sci. USA. 96:2645-2650.
29. Browder, T., et al. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878-1886.
30. Berger, J., and Moller, D.E. 2002. Mechanism of action of PPARs. Annu. Rev. Med. 53:409-435.
31. Ribatti, D., Vacca, A., Roncali, L., and Dammacco, F. 2000 The chick embryo chorioallantoic membrane as a model for in vivo research on antiangiogenesis. Curr. Pharm. Biotechnol. 1:73-82.
32. Folkman, J. 2001. Angiogenesis-dependent diseases. Semin. Oncol. 28:536-542.
33. Hlatky, L., Hahnfeldt, P., and Folkman, J. 2002. Clinical application of antiangiogenic therapy: microvessel density, what it does and does not tell us. J. Natl. Cancer Inst. 94:883-893.
34. Pihan, G.A., et al. 1998. Centrosome defects and genetic instability in malignant minors. Cancer Res. 58:3974-3985.
35. Elbrecht, A., et al. 1996. Molecular cloning, expression and characterizasion of human peroxisome proliferator activated receptors γ1 and γ2. Biochem. Biophys. Res. Commun. 224:431-437.
36. Freed, M.I., Allen, A., Jorkasky, D.K., and DiCicco, R.A. 1999. Systemic exposure to rosiglitazone is unaltered by food. Eur. J. Clin. Pharmacol. 55:53-56
37. Sietta-Honigmann, M.R., et al. 1998. Biological action of leptin as an angiogenic factor. Science. 281:1683-1686.
38. Zhang, M., Volpert, O., Shi, Y.H., and Bouck, N. 2000. Maspin is an angiogenesis inhibitor. Nat. Med. 6:196-199.
39. Jimenez, B., et al. 2000. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6:41-48.
40. Morikawa, S., et al. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J. Pathol. 160:985-1000.
41. Sunderkotter, C., Steinbrink, K., Goebeler, M., Bhardwaj, R., and Sorg, C. 1994. Macrophages and angiogenesis. J. Leukoc. Biol 55:410-422.
42. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation Nature 391:79-82.
43. Pasceri, V., Wu, H.D., Willerson, J.T., and Yeh, E.T.H. 2000. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 101:235-238.
44. Drixler, T.A., et al. 2000. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepasectomy. Cancer Res. 60:1761-1765
45. Klement, G., et al. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained rumor regression without overt toxicity. J. Clin. Invest. 105:15-24.
46. Clay, C.E., et al. 2001. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig. Med. 49:413-420.
47. Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:327-336.
48. Fahmi, H., Pelletier, J.P., and Martel-Pelletier, J. 2002. PPARγ ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. J. Rheumatol. 29:3-14.